Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Morrison & Foerster advised Santen Pharmaceutical Co., Ltd., a company dedicated to ophthalmology, in its acquisition of Eyevance Pharmaceuticals Holdings Inc., a company that develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment, through Santen’s wholly owned U.S. subsidiary for $225 million.

Morrison & Foerster advises Santen Pharmaceutical Co., Ltd in $225 million share purchase agreement with Eyevance Pharmaceuticals Holdings Inc.

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Morrison & Foerster advised Santen Pharmaceutical Co., Ltd., a company dedicated to ophthalmology, in its acquisition of Eyevance Pharmaceuticals Holdings Inc., a company that develops and commercializes topical ophthalmic products targeting the ocular surface and anterior segment, through Santen’s wholly owned U.S. subsidiary for $225 million.The MoFo deal team is led by San Francisco corporate partner Jackie Liu, with additional support from corporate associates Michael G. Williams and James Lee, and technology transactions partner Masato Hayakawa.Read Santen’s press release about the transaction: <a href="https://www.prnewswire.com/news-releases/santen-and-us-ophthalmic-company-eyevance-enter-into-share-purchase-agreement-301132757.html" target="_blank">Santen and U.S. Ophthalmic Company Eyevance Enters into Share Purchase Agreement</a>.

Morrison & Foerster advises Santen Pharmaceutical Co., Ltd in $225 million share purchase agreement with Eyevance Pharmaceuticals Holdings Inc.